advertisement
canada has been selected as a participant in a phase iii clinical trial studying the safety and efficacy of one of roche ’s portfolio of medicines in hospitalized adult patients with severe covid-19 pneumonia. in addition, roche is collecting and compiling data from other, independently-led clinical trials that are taking place around the world.
johnson and johnson (j&j) has expanded its collaboration with the u.s. department of health and human services to accelerate research on a potential covid-19 vaccine, leveraging the same innovative technology used for the company’s investigational ebola vaccine.
glaxosmithkline (gsk) is working with the coalition for epidemic preparedness innovations (cepi) on a new collaboration aimed at developing a vaccine. gsk is also collaborating with clover biopharmaceuticals, a china-based global biotech company, which has commercial scale bio-manufacturing capabilities to rapidly produce large-quantities of a potential vaccine for covid-19.
advertisement
eli lilly and canadian biotech firm abcellera have entered into an agreement to co-develop antibody products for the treatment and prevention of covid-19. the collaboration will leverage abcellera’s rapid pandemic response platform, and lilly’s global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.
abbvie is working in partnership with health authorities and institutions in several countries to evaluate hiv medicine as a covid-19 treatment.
medicago , a montreal-based company, has announced the production of a potential vaccine candidate for covid-19, which is undergoing preclinical testing for safety and efficacy.
pfizer has outlined a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat covid-19. the plan will help scientists more rapidly bring forward therapies and vaccines to protect humankind from this escalating pandemic and prepare the industry to better respond to future global health crises.
sanofi and partner regeneron pharmaceuticals inc have started a clinical trial of their rheumatoid arthritis drug kevzara as a treatment for the coronavirus. through sanofi’s partnership with biomedical advanced research and development authority (barda), they have announced plans to leverage some of its previous development work for a sars vaccine, hoping to unlock a fast path forward for developing a vaccine.
advertisement
takeda is developing an experimental drug to treat people infected with covid-19, as well as those at high risk, by using the blood of those who have recovered from the virus and the antibodies they developed in their immune systems to defeat the infection.
advertisement